ClinicalTrials.gg
RecruitingNCT06228196Updated Feb 26, 2024

Cohort Study of Clinical and Neuroimaging Characteristics for BPPV Patients in China

An observational study in BPPV, Vertigo and Vertigo, Peripheral, sponsored by First Affiliated Hospital Xi'an Jiaotong University. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-26.

Sponsored by First Affiliated Hospital Xi'an Jiaotong University · Observational

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The main objective is to analyze the abnormality of physical condition, mental health and blood examination of the patients with benign paroxysmal positional vertigo (BPPV). Besides, the investigators aim to establish a database of BPPV based on multimodal magnetic resonance imaging data in the brain to identify high-risk patients with residual dizziness (RD) and systematically establish the comprehensive assessment system for the precise diagnosis, treatment and recovery of RD, optimize the tactics of BPPV management in China.

Read the detailed description

This is an observational, longitudinal, and single-center study. Confirmed BPPV cases will complete the following programs before and after 1 and 6 months of treatment for exploring biological mechanism and predictive biomarkers of BPPV: 1) fill in the behavioral psychological scales, 2) submit blood samples at a local laboratory, 3) receive 3 times brain MRI scan. The healthy controls will complete the same programs as BPPV-group mentioned above only at the time of inclusion. The investigators will establish the brain MRI database containing neuropsychological scales and blood parameters of BPPV in China.

02

Conditions studied

  • BPPV
  • Vertigo
  • Vertigo, Peripheral

Browse trials for

Keywords

  • BPPV
  • residual dizziness
  • Vertigo
  • Neuroimaging
  • Epidemic
03

In context

Vertigo

187 studies on the registry are indexed under Vertigo; 27 are open to participants now.

This study's planned enrollment of 150 is below the median of 198 across 42 observational studies indexed under Vertigo.

Browse Vertigo studies →

Lead sponsor

First Affiliated Hospital Xi'an Jiaotong University is the lead sponsor of 314 studies on the registry; 87 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study will be carried out in the First Affiliated Hospital Xi'an Jiaotong University for patients who had diagnosis of BPPV by the Dix-Hallpike maneuver or Supine Roll test.

The healthy control population will be searched in the primary care services, media and social networks.

All participants will sign informed consent.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of BPPV/Healthy subjects who have not had BPPV

Exclusion criteria

Exclusion Criteria:

  • History of organic diseases in central nervous system and mental disorder, such as tumors, infections, depressive disorder, schizophrenia, etc. Claustrophobic
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • BPPV patients

    Confirmed diagnosis of BPPV

    Device: Simultaneous cortico-spinal magnetic resonance imaging, Serum

  • Healthy controls

    Healthy subjects who have not had BPPV

    Device: Simultaneous cortico-spinal magnetic resonance imaging, Serum

Interventions

  • DeviceSimultaneous cortico-spinal magnetic resonance imaging, Serum

    Simultaneous cortico-spinal magnetic resonance imaging data were collected in a strong magnetic field and collected the serum of participants.

06

What researchers measure

Primary outcomes

  1. Differences between patients with BPPV and control group in brain structure

    The changes of brain volume (mm3) are evaluated by structural MRI

    Time frame: baseline and 1 and 6 months

  2. Differences between two groups in brain function

    The changes of brain functional connectivity intensity are evaluated by functional MRI

    Time frame: baseline and 1 and 6 months

  3. Changes on vertigo symptoms

    Vertigo is assessed with the Dizziness Handicap Inventory (DHI Scale)

    Time frame: baseline and 1 and 6 months

  4. Changes on vertigo symptoms

    Vertigo is also assessed with the Activities-specific Balance Confidence Scale (ABC Scale)

    Time frame: baseline and 1 and 6 months

  5. Changes on vertigo symptoms

    Vertigo is also assessed with the Visual Vertigo Analogue Scale (VVAS)

    Time frame: baseline and 1 and 6 months

  6. Difference in blood markers between the two groups

    All subjects underwent fasting vein blood collection of about 5 ml at about 8 a.m. Blood indices related to BPPV and related clinical symptoms were screened, the inflammatory index is interleukin-6(IL-6)

    Time frame: baseline and 1 and 6 months

  7. Difference in blood markers between the two groups

    Immunology-related index in the blood sample is superoxide dismutase (SOD)

    Time frame: baseline and 1 and 6 months

  8. Difference in blood markers between the two groups

    Inflammatory index in the blood sample is neutrophils/lymphocytes

    Time frame: baseline and 1 and 6 months

Secondary outcomes

  1. Differences in Fatigue between the two groups

    Fatigue is assessed with the Multidimensional Fatigue Inventory (MFI). A higher score represents a worse outcome. The MFI is a 20-item self-report instrument covering four dimensions (general fatigue, physical fatigue, mental fatigue, reduced motivation and reduced activity) designed to measure fatigue.

    Time frame: baseline and 1 and 6 months

  2. Differences in Sleep between the two groups

    Sleep quality is assessed with Pittsburgh Sleep Quality Index (PSQI). A higher score corresponding to a worse sleep quality.

    Time frame: baseline and 1 and 6 months

  3. Differences in cognition between the two groups

    The cognition is assessed with Montreal Cognitive Assessment (MoCA). Higher scores (0-30) are related to a better performance.

    Time frame: baseline and 1 and 6 months

  4. Differences in executive function between the two groups

    The executive function is assessed with Trail Making Test A and B. Participants are asked to connect sequential numbers (TMT-A) and interconnect sequential numbers and letters (TMT-B).

    Time frame: baseline and 1 and 6 months

  5. Difference in anxiety between the two groups

    Anxiety is assessed with Beck Anxiety Inventory (BAI). A higher score corresponding to more severe anxiety symptoms.

    Time frame: baseline and 1 and 6 months

  6. Difference in depression between the two groups

    Depression is assessed with the Patient Health Questionnaire-9 (PHQ-9). A higher score corresponding to more severe depression symptoms.

    Time frame: baseline and 1 and 6 months

  7. Differences in verbal memory and working memory between the two groups

    Verbal memory is assessed with the Auditory Verbal Learning Test (AVLT). A 12-word list are read by examiner three times and participants are asked to recall them followed by each presentation, which was called "immediate recall". The "short delayed recall" and "long delayed recall" ask the participants to recall the above 12-word list 5 minutes and 20 minutes later, the correctly recalled number of words are recorded. Finally, the subjects are instructed to recognize the learned words from a 24-words list which consisted of above learned 12-words list and a new unlearned 12-words list. Working memory is assessed with the Digit Span Backward. Participants are asked to repeat the numbers in the reverse order the examiner read them aloud and a higher score corresponding to a better outcome.

    Time frame: baseline and 1 and 6 months

  8. Differences in auditory attention between the two groups

    Auditory attention is assessed with the Digit Span Forward. Participants are asked to repeat the numbers in the order the examiner read them aloud and a higher score corresponding to a better outcome.

    Time frame: baseline and 1 and 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Jun 2026, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2024
First posted
Jan 29, 2024
StartActual
Jan 8, 2024
Primary completionEst.
Jun 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Feb 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06228196
Responsible party
Sponsor
First posted
Jan 29, 2024
Start date
Jan 8, 2024
Primary completion
Jun 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Feb 26, 2024

Study contacts

Yuan Wang, M.D.
Contact
wangyuan8003@126.com
0086-13324598144
Ming Zhang, PhD
Contact
zmmri@163.com
+8618991232265
Yuan Wang, M.D.
principal investigator · First Affiliated Hospital of Xian Jiaotong University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion